Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cilazapril monohydrate
Drug ID BADD_D00465
Description Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.
Indications and Usage Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.
Marketing Status approved
ATC Code C09AA08
DrugBank ID DB01340
KEGG ID D07699; D01069
MeSH ID D017315
PubChem ID 56329
TTD Drug ID D04GKO
NDC Product Code Not Available
UNII 19KW7PI29F
Synonyms Cilazapril | Cilazapril Monohydrobromide | Cilazapril, Anhydrous | Cilazapril Anhydrous | Cilazapril Monohydrate | Ro 31-2848 | Ro 31 2848 | Ro 312848 | Ro-31-2848 | Ro312848 | Cilazapril Hydrate | Cilazapril, (S*)-Isomer | Inhibace
Chemical Information
Molecular Formula C22H33N3O6
CAS Registry Number 92077-78-6
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC2CCCN3CCCC(N3C2=O)C(=O)O.O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Polyuria20.02.03.002---
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Rash23.03.13.001---
Rash erythematous23.03.13.029---
Rash maculo-papular23.03.13.004--
Rectal haemorrhage07.12.03.001; 24.07.02.018--
Renal artery stenosis20.01.07.005; 24.04.11.001---
Renal failure20.01.03.005---
Renal pain20.02.03.003---
Rhinitis11.01.13.004; 22.07.03.006--
Scleroderma10.04.07.001; 15.06.01.002; 23.03.02.005---
Shock24.06.02.002---
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006---
Tachycardia02.03.02.007---
Tension19.06.02.005---
Thrombocytopenia01.08.01.002---
Thrombocytopenic purpura01.08.01.003; 23.06.01.007---
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Tremor17.01.06.002--
Urethral disorder20.07.01.002---
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages